The clinical significance of circulating tumor cell in metastatic Non-Small Cell Lung Cancer

The clinical significance of circulating tumor cell in metastatic Non-Small Cell Lung Cancer - Circulating Tumor Cell in Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001896

Enrollment

160

Registered

2009-04-18

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically or cytologically confirmed non-small cell lung cancer 2) metastatic disease 3) chemotherapy is scheduled 4) any prior treatment is permitted 5) more than 2 weeks since last administration of chemotherapy 6) measurable disease 7) age: over 20 8) life expectancy: more than 3 months 9) written informed consent

Exclusion criteria

Exclusion criteria: 1) chemotherapy including amurubicin 2) Uncontrolled pleural effusion 3) symptomatic brain metastases 4) active concomitant malignancy 5) serious concurrent illness, such as hypertension, angina pectoris, myocardial infarction, or severe infection 6) pregnant/lactating women 7) history of severe drug allergy 8) psychiatric disease

Design outcomes

Primary

Measure	Time frame
To clarify the relation between CTC and tumor response.	—

Secondary

Measure	Time frame
To clarify the relation between CTC and progression-free survival or overall survival.	—

Countries

Japan

Contacts

Public ContactYoung Hak Kim

Graduate School of Medicine, Kyoto University Department of Respiratory Medicine

075-751-3830

Outcome results